Cannell Capital LLC Has $10.35 Million Holdings in OraSure Technologies, Inc. (NASDAQ:OSUR)
Cannell Capital LLC raised its position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR – Free Report) by 161.0% in the second quarter, according to its most recent filing with the SEC. The firm owned 2,066,690 shares of the medical instruments supplier’s stock after purchasing an additional 1,274,773 shares during the quarter. OraSure Technologies makes up approximately 2.1% of Cannell Capital LLC’s investment portfolio, making the stock its 19th largest holding. Cannell Capital LLC owned approximately 2.81% of OraSure Technologies worth $10,354,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Assenagon Asset Management S.A. boosted its holdings in shares of OraSure Technologies by 18.7% during the 2nd quarter. Assenagon Asset Management S.A. now owns 487,396 shares of the medical instruments supplier’s stock worth $2,442,000 after buying an additional 76,822 shares in the last quarter. Brandywine Global Investment Management LLC bought a new position in shares of OraSure Technologies during the 2nd quarter worth approximately $746,000. Acadian Asset Management LLC boosted its holdings in shares of OraSure Technologies by 253.8% during the 1st quarter. Acadian Asset Management LLC now owns 1,067,241 shares of the medical instruments supplier’s stock worth $6,451,000 after buying an additional 765,595 shares in the last quarter. Trexquant Investment LP lifted its holdings in shares of OraSure Technologies by 277.7% in the 2nd quarter. Trexquant Investment LP now owns 62,595 shares of the medical instruments supplier’s stock worth $314,000 after purchasing an additional 46,022 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its holdings in shares of OraSure Technologies by 319.9% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 73,724 shares of the medical instruments supplier’s stock worth $369,000 after purchasing an additional 56,167 shares in the last quarter. Institutional investors and hedge funds own 88.76% of the company’s stock.
Analysts Set New Price Targets
A number of brokerages recently issued reports on OSUR. StockNews.com cut OraSure Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, November 8th. TheStreet upgraded OraSure Technologies from a “d+” rating to a “c” rating in a report on Wednesday, November 8th. Finally, JPMorgan Chase & Co. lowered their price target on OraSure Technologies from $6.00 to $5.00 and set a “neutral” rating for the company in a research report on Wednesday, November 8th.
View Our Latest Report on OraSure Technologies
OraSure Technologies Stock Up 3.0 %
NASDAQ OSUR traded up $0.21 on Friday, reaching $7.10. The company had a trading volume of 482,807 shares, compared to its average volume of 597,607. The stock has a market capitalization of $521.74 million, a P/E ratio of 10.76 and a beta of 0.22. The company’s fifty day moving average is $6.20 and its 200 day moving average is $5.75. OraSure Technologies, Inc. has a 52-week low of $4.38 and a 52-week high of $7.82.
OraSure Technologies (NASDAQ:OSUR – Get Free Report) last released its quarterly earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of $0.07 by $0.20. OraSure Technologies had a return on equity of 14.88% and a net margin of 10.86%. The business had revenue of $89.18 million during the quarter, compared to analyst estimates of $74.56 million. During the same period in the prior year, the firm posted $0.07 EPS. OraSure Technologies’s quarterly revenue was down 23.4% compared to the same quarter last year. On average, research analysts expect that OraSure Technologies, Inc. will post 0.79 EPS for the current year.
OraSure Technologies Company Profile (Free Report)
OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider OraSure Technologies, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and OraSure Technologies wasn’t on the list.
While OraSure Technologies currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.